๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shenzhen Geno-Immune Medical Institute43 Beijing Biotech32 Sun Yat-sen University23 Bristol-Myers Squibb19 Shenzhen University General Hospital11
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shenzhen

576 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.
Phase 2
75
Baotou, Beijing, Guangzhou, Hangzhou, Nanchang, Shenzhen
2025-11-26
Recruiting
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
NCT07279493Acute Ischemic Stroke
Kunming Pharmaceuticals, Inc.
Phase 2
300
Beijing, Shenzhen, Cangzhou, Hengshui, Daqing, Anyang, Nanyang, Xuzhou
2025-11-22
Recruiting
Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients
NCT07252102Liver Cirrhosis, Polyps of Colon, Gastrointestinal Dysfunction
Zhejiang University
Not applicable
450
Shenzhen, Hangzhou
2025-11-20
Recruiting
Neuroendoscopy-assisted Drainage Versus Burr Hole Drainage for Chronic Subdural Hematoma
NCT07144423Chronic Subdural Hematoma
Beijing Tiantan Hospital
Not applicable
770
Beijing, Xiamen, Jiangmen, Shantou, Shenzhen, Liuzhou, Nanning, Wuzhou
2025-11-19
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
DrugsLeucovorin·Oxaliplatin·Bevacizumab
Summit Therapeutics
Phase 3
600
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Haikou, Shijiazhuang, Harbin
2025-11-18
Active, closed
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xiโ€™an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
Recruiting
Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss
NCT07505667Sudden Hearing Loss, Sensorineural Hearing Loss
Guangdong Provincial People's Hospital
Not applicable
128
Guangzhou, Shenzhen, Zhongshan, Liuzhou, Ganzhou
2025-11-15
Recruiting
Jockey Club Support Project
NCT07136064Family Relations, Resilience, Emotion Regulation
City University of Hong Kong
Not applicable
450
Shenzhen
2025-11-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
Real-world Study of Aflibercept 8 mg in nAMD
NCT07640997Neovascular Age-Related Macular Degeneration (nAMD)
DrugAflibercept
Peking University People's Hospital
Observational
300
Beijing, Fuzhou, Shenzhen, Zunyi, Harbin, Nanyang, Wuhan, Hohhot
2025-11-11
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161ANCA Associated Vasculitis (AAV)
DrugsAzathioprine·Prednisone·Rituximab·Cyclophosphamide
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
300
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen
2025-11-10
Recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
NCT07223840Smoking
DrugBrenipatide
Eli Lilly and Company
Phase 2
222
Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen
2025-11-03
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440Fabry Disease
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Active, closed
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407Non-cystic Fibrosis Bronchiectasis
AstraZeneca
Observational
251
Beijing, Chongqing, Quanzhou, Lanzhou, Shenzhen, Zhanjiang, Nanning, Guiyang
2025-10-27
Recruiting
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
NCT07775820Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou, Shenzhen, Nanchang, Wenzhou
2025-10-20
Recruiting
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2025-10-16
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
DrugBMS-986504
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis.
NCT07198555Knee Osteoarthritis
Belief BioMed (Beijing) Co., Ltd
Phase 1
81
Shenzhen, Shanghai
2025-10-09
Active, closed
Intervention to Reduce Sedentary Behavior During School Recess Among Adolescents
NCT07451535Sedentary Behaviour, Physical Activity, Adolescents, School-based Intervention
South China Normal University
Not applicable
1,000
Foshan, Guangzhou, Shenzhen, Zhuhai, Haikou, Jinzhong, Jinzhou
2025-10-08
Not yet open
Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP
NCT07200336Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugMepolizumab
Eye & ENT Hospital of Fudan University
Phase 4
360
Chongqing, Fuzhou, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2025-10-08
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Not yet open
TENS for Limb Function in Stroke: Design and Rationale for a Randomized Trial
NCT06997744Stroke
CHENGNING Song
Not applicable
156
Shenzhen
2025-10-01
Not yet open
Endoscopic Cardial Constriction Ligation (ECCL) for Refractory GERD Using a Disposable Endoscope
NCT07176221Gastroesophageal Reflux Disease (GERD)
Ying Zhu
Not applicable
46
Shenzhen
2025-10-01
Recruiting
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugTQC2731
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb
Phase 3
3,040
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin
2025-09-22
Recruiting
A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes
NCT07203599Androgenic Alopecia
DrugMinoxidil
Shenzhen People's Hospital
Phase 1/2
59
Shenzhen
2025-09-20
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
Baotou, Beijing, Guangzhou, Shenzhen
2025-09-19
Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age โ‰ฅ60
First Affiliated Hospital of Zhejiang University
Phase 2
25
Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou
2025-09-16
Recruiting
Prenatal Music Exposure to Enhance Postnatal Language Development
NCT07699536Pregnancy
Chinese University of Hong Kong
Not applicable
480
Shenzhen
2025-09-15
Not yet open
Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors
NCT07182435Solid Tumor Malignancies
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase EARLY_PHASE1
36
Shenzhen
2025-09-15
Recruiting
Total Energy Expenditure Across the Life Course in Low-and Middle-Income Countries -- Chinese Children
NCT07054294Nutrition, Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
70
Shenzhen
2025-09-15
Not yet open
Reinforcement Learned Automated Anesthesia Systems During Painless Abortion
NCT07132151Painless Abortion, Artificial Intelligence (AI), Ciprofol
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Not applicable
167
Fuzhou, Jinjiang, Quanzhou, Shenzhen, Zhengzhou, Chengdu, Chongqing
2025-09-08
Recruiting
Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants
NCT07174830Healthy Participants
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 4
54
Shenzhen
2025-09-06
Recruiting
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
NCT07137910Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Recruiting
Clinical Outcomes After Non-curative Endoscopic Resection in Early Colorectal Cancer: A Multicenter Study
NCT07542171Early Colorectal Cancer, Non-curative Endoscopic Resection
Nanfang Hospital, Southern Medical University
Observational
400
Guangzhou, Shenzhen, Haizhu
2025-09-03
Active, closed
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNฮฑ for the Treatment of Hepatitis B
NCT07135349Chronic Hepatitis B
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
209
Hefei, Beijing, Sichuan, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi
2025-09-02
Recruiting
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
NCT07093814Glioblastoma
DrugVRT106
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1/2
42
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhuhai, Nanning, Jinan
2025-09-02
Active, closed
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
NCT07060885Allergic Rhinoconjunctivitis, Allergic Rhinitis
ALK-Abellรณ A/S
Phase 3
327
Beijing, Fuzhou, Guangzhou, Shenzhen, Zhuhai, Nanning, Haikou, Changshacun
2025-09-01
Not yet open
The Impact of Various Exercise Intensities on Energy Expenditure Metabolism
NCT07137520Physical Activity
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
100
Shenzhen
2025-09-01
Not yet open
Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection
NCT07156656Type A Aortic Dissection, Organ Failure, Multiple
Shanghai Zhongshan Hospital
Phase 4
236
Hefei, Fuzhou, Guangzhou, Shenzhen, Xi'an, Shanghai
2025-09-01
Recruiting
We-INtervention Among Chinese HIV-serodiscordant Male Couples
NCT06639932HIV
City University of Hong Kong
Not applicable
320
Xiamen, Guangzhou, Shenzhen, Chengdu
2025-09-01
Not yet open
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
NCT07192848Hepatocellular Carcinoma Non-resectable
Song Peng
Phase 2
47
Shenzhen
2025-09
Not yet open
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
NCT07131150Idiopathic Pulmonary Fibrosis (IPF)
Ruijin Hospital
Phase 2
66
Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing
2025-08-31
Recruiting
A Study of SKB518 in Patients With Lung Cancer
NCT07019675Lung Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
192
Shenzhen, Nanning, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanchang, Jinan
2025-08-29
Recruiting
LineMatrixยฎ Biological Vascular Graft for the Creation of Arteriovenous Graft
NCT07773051Arteriovenous Graft
Longhua Hospital
Not applicable
326
Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang
2025-08-25
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
DrugBudoprutug
Climb Bio, Inc.
Phase 2
45
Beijing, Shenzhen, Wuxi, Xi'an, Jinan, Yantai, Yibin
2025-08-25
Recruiting
Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients
NCT07126470Cataract, Retinitis Pigmentosa (RP)
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
88
Guangzhou, Shenzhen, Wuhan
2025-08-25
Recruiting
Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
NCT07097818Type 1 Diabetes
Second Xiangya Hospital of Central South University
Not applicable
400
Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang
2025-08-18
Recruiting
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
NCT07120464Rabies Exposure, Immunocompromised, Chronic Disease
Liaoning Chengda Biotechnology CO., LTD
Observational
180
Shenzhen
2025-08-15
Recruiting
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023Breast Cancers
DrugsPertuzumab/Trastuzumab·Paclitaxel
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
112
Beijing, Guangzhou, Shantou, Nanning, Guiyang, Haikou, Wenzhou, Shenzhen
2025-08-15
Recruiting
Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study
NCT07284264Dementia
Xuanwu Hospital, Beijing
Observational
6,000
Beijing, Hainan, Ningxiang, Shenyang, Shenzhen, Yichun
2025-08-15
Recruiting
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
NCT06896708Chronic Coronary Syndrome
Liu yong
Not applicable
766
Chongqing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Dalian
2025-08-12
Recruiting
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease
NCT07031531Premature Coronary Heart Disease
China National Center for Cardiovascular Diseases
Not applicable
4,900
Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou
2025-08-08
Recruiting
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
NCT06615596Atrial Fibrillation (AF)
China National Center for Cardiovascular Diseases
Phase EARLY_PHASE1
3,160
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Shanghai, Taiyuan, Chengdu
2025-08-05
Active, closed
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUSยฎ PLUS (Shenzhen)
NCT07153094Solid Tumor, Adult
Ion Beam Applications
Not applicable
47
Shenzhen
2025-08-04
Recruiting
Real World Evidence Study of SYN023 in Children Exposed to Rabies
NCT07327307Rabies Post-exposure Prophylaxis
Synermore Biologics (Suzhou) Co., Ltd.
Observational
232
Beijing, Shenzhen, Changsha, Hengyang, Nanchang
2025-08-02
Recruiting
The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study
NCT07089173Hemodynamics
DrugsLidocaine·Sufentanil
Peking University Shenzhen Hospital
Not applicable
99
Shenzhen
2025-08-01
Not yet open
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
NCT07101549Advanced Solid Tumors
changjianhua
Phase 1
25
Shenzhen
2025-08-01
Not yet open
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739Primary Immune Thrombocytopenia
DrugTQB3473
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
320
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-08
Recruiting
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
NCT07128914Solid Tumor Malignancies
GeneSail Biotech (Shanghai) Co., Ltd.
Phase 1
32
Hefei, Fuzhou, Shenzhen, Zhengzhou, Changsha, Shanghai
2025-07-31
Recruiting
Repetitive Transcranial Magnetic Stimulation and Postoperative Neurocognitive Recovery
NCT06482749Older Patients, Cognitive Impairment, Repetitive Transcranial Magnetic Stimulation, Delayed Neurocognitive Recovery
Peking University First Hospital
Not applicable
568
Beijing, Shenzhen, Xi'an
2025-07-28
Recruiting
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
416
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen
2025-07-25
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
DrugAbrocitinib
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography
NCT07133516Artificial Intelligence (AI), Artificial Intelligence (AI) in Diagnosis, Cardiovascular Diseases (CVD), Echocardiography
First Hospital of China Medical University
Observational
1,600
Huainan, Fuzhou, Meizhou, Shantou, Shenzhen, Baise City, Guilin, Liuzhou
2025-07-22
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Oxaliplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
477
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen
2025-07-16
Recruiting
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07039669Pulmonary Disease, Chronic Obstructive (COPD)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
594
Beijing, Shenzhen, Nanjing, Hangzhou
2025-07-16
Recruiting
Incidence of Postoperative Cognitive Decline in Patients With Preexisting Cognitive Impairment
NCT07135336Cognitive and Behavioral Impairment
Peking University Shenzhen Hospital
Observational
340
Shenzhen
2025-07-15
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
DrugMezagitamab
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangzhou, Shenzhen, Changsha, Baotou, Nanjing
2025-07-15
Recruiting
Effect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes
NCT07007676Diabetes Mellitus Type 2
Shanghai 6th People's Hospital
Not applicable
148
Shenzhen
2025-07-14
Recruiting
Light Therapy on Pain and Synovitis
NCT07057063Knee Pain Chronic, Synovitis of Knee, Light Therapy
The Hong Kong Polytechnic University
Not applicable
80
Shenzhen
2025-07-13
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai
2025-07-10
Recruiting
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
NCT07202728Hydatidiform Mole
Obstetrics & Gynecology Hospital of Fudan University
Observational
1,489
Lanzhou, Shenzhen, Haikou, Shijiazhuang, Zhengzhou, Dalian, Shenyang, Jinan
2025-07-09
Recruiting
Safety and Efficacy of Ventricular Irrigation for Ventriculitis
NCT06358209Central Nervous System Infections
RenJi Hospital
Not applicable
310
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin
2025-07-01
Recruiting
Total Energy Expenditure in Healthy Chinese Populations: A Nationwide Study Using the Doubly Labelled Water Method
NCT07178054Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
240
Chongqing, Shenzhen, Haikou, Hohhot, Shenyang, Qingdao, Tacheng
2025-07-01
Recruiting
The Effective Blood Concentration of Ciprofol
NCT07294989Thyroid Disease
DrugCiprofol
Peking University Shenzhen Hospital
Observational
101
Shenzhen
2025-07-01
Recruiting
Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells
NCT07041801Systemic Lupus Erythematosus (SLE)
DrugMedium
Shenzhen Beike Bio-Technology Co., Ltd.
Phase 1/2
58
Shenzhen
2025-06-28
Recruiting
Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients
NCT07004686Opioid Use
Peking University Shenzhen Hospital
Not applicable
112
Shenzhen
2025-06-28
Recruiting
Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality
NCT07002723Hip Fractures
DrugsEsketamine·Midazolam
Peking University Shenzhen Hospital
Not applicable
96
Shenzhen
2025-06-20
Recruiting
A PAN-USR TB Multi-Center Trial
NCT06905522Pulmonary Tuberculosis
DrugsPretomanid·Sitafloxacin·Bedaquiline·Ethambutol
Shenzhen Third People's Hospital
Phase 3
610
Beijing, Shenzhen, รœrรผmqi
2025-06-18
Recruiting
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
NCT07069569Chronic Hepatitis B
DrugsHepatitis B vaccine·PEG-IFNฮฑ·AHB-137
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun
2025-06-08
Recruiting
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT06891833HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
PeRsonalized Blood prEssure Management on Postoperative Complications and Mortality in hIgh-risk Patients Undergoing Major Non-cardiac Surgery
NCT06952387Hypotension
Nanfang Hospital, Southern Medical University
Not applicable
1,624
Guangzhou, Shenzhen, Zhuhai, Xiโ€™an, Hangzhou
2025-06-03
Recruiting
Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
NCT07326930Acute Lymphoblastic Leukemia ALL
The Hong Kong Polytechnic University
Observational
173
Zhengzhou, Shanghai, Shenzhen
2025-06-02
Recruiting
Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT07040098Locally Advanced Rectal Cancer (LARC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
228
Beijing, Shenzhen
2025-06-01
Active, closed
A Clinical Study on The Use of DL-endopeptidase-producing Probiotics as an Adjunctive Therapy for Inflammatory Bowel Disease.
NCT07318753Inflammatory Bowel Disease (IBD)
Shenzhen Hospital of Southern Medical University
Not applicable
300
Shenzhen
2025-06-01
Active, closed
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsChlorambucil·Tacabrutideg·Methylprednisolone·Bendamustine
BeOne Medicines
Phase 3
153
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning
2025-05-29
Recruiting
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
NCT06971094SMA - Spinal Muscular Atrophy
GeneCradle Inc
Phase 3
50
Beijing, Shanghai, Shenzhen, Suzhou, Wuhan
2025-05-27
Recruiting
Implementation of Machine Learning and Hemodynamic Profiles Based Clinical Decision Support Systems for Personalized Guideline Accordant Antihypertensive Regimens in Primary Care: a Pragmatic Cluster Randomized Controlled Trial
NCT06828692Hypertension
China National Center for Cardiovascular Diseases
Not applicable
2,160
Shenzhen
2025-05-26
Recruiting
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
NCT07040228Pancreatic Cancer Metastatic
DrugRegorafenib
Junjie Hang
Phase 1/2
23
Shenzhen
2025-05-26
Active, closed
A Study for the Evaluation of Efficacy and Safety of Proliaยฎ in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153Glucocorticoid-induced Osteoporosis
DrugsProlia·Denosumab
Amgen
Phase 4
102
Beijing, Guangzhou, Shenzhen, Luoyang, Wuhan, Changzhou, Huaian, Nantong
2025-05-24
Recruiting
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
NCT07023484Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsCarboplatin·Paclitaxel
The University of Hong Kong
Phase 2
126
Guangzhou, Shenzhen
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning
2025-05-22
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Guangzhou, Hangzhou, Hengyang, Nanning, Shenzhen, Taiyuan, Tianjin, Zhengzhou
2025-05-19
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis
NCT06437600Stroke, Acute Ischemic
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
412
Guangzhou, Shenzhen
2025-05-08
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Recruiting
Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads
NCT06947356Hepatitis B
Guangzhou 8th People's Hospital
Not applicable
210
Guangzhou, Shenzhen, Shijiazhuang, Changsha, Wenzhou, Beijing
2025-05-03
Recruiting
The Effect of Exercise on Metabolic Alteration
NCT06923163Sedentary Behavior, Healthy Participants, Adult
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Not applicable
80
Shenzhen
2025-05-01
Recruiting
TEEM-GIFTS: A Gamified mHealth to Reduce Post-Discharge Suicide Risk
NCT06358339Suicide
Shenzhen Kangning Hospital
Not applicable
640
Shenzhen
2025-05-01
Rows per page Showing 201–300 of 576
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 576 of those studies with a site in Shenzhen.

How many clinical trials are recruiting in Shenzhen?

337 of the 576 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 115 have not yet opened recruitment, 109 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.